Ask Warren

Hyundai Bioscience

048410 · KOSDAQ · ₩048410 · 현대바이오

₩5,370▼ ₩300 (5.29%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩520M₩325M₩1.9B₩553M₩333M₩709M₩366M₩459M
Cost of sales₩685M₩393M₩1.9B₩599M₩297M₩516M₩221M₩502M
Gross profit−₩164M−₩68M₩61M−₩46M₩36M₩193M₩145M−₩43M
Operating income−₩5.5B−₩4.7B−₩4.4B−₩4.6B−₩4.8B−₩4.3B−₩2.8B−₩3.3B
Net income−₩12B−₩5.3B−₩4.7B−₩7B−₩4.3B−₩6.1B−₩4.6B−₩5.1B
Net income to shareholders−₩12B−₩5.3B−₩4.7B−₩7B−₩4.3B−₩6.1B−₩4.6B−₩5.1B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩131B₩129B₩131B₩117B₩120B₩142B₩68B₩71B
Current assets₩44B₩40B₩44B₩36B₩39B₩82B₩6.8B₩9.1B
Cash and equivalents₩17B₩8.1B₩22B₩8.9B₩12B₩63B₩3.7B₩8.1B
Total liabilities₩28B₩17B₩20B₩6.3B₩5.4B₩25B₩28B₩27B
Current liabilities₩19B₩17B₩20B₩5.6B₩4.7B₩24B₩27B₩26B
Borrowings₩21B₩15B₩17B₩2.8B₩2.7B₩22B₩26B₩25B
Total equity₩103B₩112B₩111B₩110B₩114B₩118B₩39B₩44B
Shareholders' equity₩103B₩112B₩111B₩110B₩114B₩118B₩39B₩44B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩5.4B−₩2.1B−₩5.5B−₩3.5B−₩4.6B−₩3.4B−₩4B₩6B
Free cash flow−₩5.4B−₩2.1B−₩5.5B−₩3.5B−₩4.6B−₩3.4B−₩4B₩6B

Consolidated where available. Amounts in won.

Also known as: Hyundai Bioscience / 현대바이오 / 048410 / KRX:048410

Source: KRX statistical information